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Prostate cancer (CaP) progresses from prostatic intraepithelial neoplasia through locally invasive adenocarcinoma to castrationresistant metastatic carcinoma 1 . Although radical prostatectomy, radiation and androgen ablation are effective therapies for androgen-dependent CaP, metastatic castration-resistant CaP is a major complication with high mortality 2 . Androgens stimulate growth and survival of prostate epithelium and early CaP. Although most patients initially respond to androgen ablation, many develop castration-resistant CaP within 12-18 months 2 . Despite extensive studies, the mechanisms underlying the emergence of castration-resistant CaP remain poorly understood and their elucidation is critical for developing improved therapies. Curiously, castration-resistant CaP remains androgen-receptor dependent, and potent androgen-receptor antagonists induce tumour regression in castrated mice 3 . The role of inflammation in castration-resistant CaP has not been addressed, although it was reported that intrinsic NF-kB activation supports its growth 4 . Inflammation is a localized protective reaction to injury or infection, but it also has a pathogenic role in many diseases, including cancer 5 . Whereas acute inflammation is critical for host defence, chronic inflammation contributes to tumorigenesis and metastatic progression. The inflammation-responsive IkB kinase (IKK)-b and its target NF-kB have important tumour-promoting functions within malignant cells and inflammatory cells 6 . The latter, including macrophages and lymphocytes, are important elements of the tumour microenvironment [7] [8] [9] , but the mechanisms underlying their recruitment remain obscure, although they are thought to depend on chemokine and cytokine production 10 . We found that CaP progression is associated with inflammatory infiltration and activation of IKK-a, which stimulates metastasis by an NF-kBindependent, cell autonomous mechanism 11 . Here we show that androgen ablation causes infiltration of regressing androgendependent tumours with leukocytes, including B cells, in which IKK-b activation results in production of cytokines that activate IKK-a and STAT3 in CaP cells to enhance hormone-free survival.
To determine whether IKK-b-driven NF-kB participates in the development of castration-resistant CaP, we conditionally deleted the Ikkb (also known as Ikbkb) gene in prostate epithelial cells of TRAMP mice, in which CaP is induced by prostate-specific expression of simian virus 40 T antigen 12 . Counter to previous expectations 4 , IKK-b ablation in prostate epithelial cells had no effect on genesis and progression of androgen-dependent CaP (Supplementary Fig. 1 ) or development of castration-resistant CaP after castration ( Supplementary Fig. 2 ). To facilitate mechanistic analysis of castration-resistant CaP development we used subcutaneous allografts of the mouse androgen-dependent CaP cell line myc-CaP, which is derived from the FVB genetic background 13 . Silencing of IKK-b in myc-CaP cells did not affect primary tumour growth or castration-resistant CaP re-growth in castrated FVB mice ( Supplementary Fig. 3 ).
By contrast, deletion of IKK-b in interferon-responsive cells upon induction of Mx1-Cre expression prevented castration-induced metastatic spread in TRAMP/Ikkb (Fig. 1a) . Concurrently, the regressing tumours were infiltrated with T and B lymphocytes, natural killer cells and myeloid cell types ( Fig. 1b and Supplementary Fig. 5 ). Infiltration was transient, declining by 2 weeks after castration. B-and T-lymphocyte infiltration was also detected in 100% of human CaP samples (untreated patients with Gleason scores of 6-8), but B cells were undetectable in normal prostate or benign prostatic hyperplasia (Fig. 1c) . The messenger RNAs for many inflammatory chemokines were also upregulated in the myc-CaP allografts, but no changes in androgen-receptor mRNA expression were found ( Supplementary Fig. 6a ). These chemokines may recruit lymphoid and myeloid cells into the regressing tumour. Indeed, antibody-mediated inhibition of CXCL13, a B-cell chemoattractant 16 , prevented castration-induced B-cell recruitment ( Supplementary Fig. 6b, c) . Inflammatory cytokine mRNAs, including interleukin (IL)-6, IL-12, TNF-a and lymphotoxin, were also upregulated in the regressing myc-CaP allograft, but only lymphotoxin expression was reduced upon CXCL13 inhibition ( Supplementary  Fig. 7 ). Castration resulted in nuclear export of androgen receptor, but after 3 weeks androgen receptor was nuclear again ( Supplementary  Fig. 8 ), suggesting it is activated at late phases of castration-resistant CaP growth despite androgen depletion.
STAT3 was proposed to promote activation of unliganded androgen receptor 17 . Indeed, STAT3 was activated during emergence of castration-resistant CaP, faster than androgen receptor (Supplementary Fig. 9 ). Mx1-Cre-mediated IKK-b deletion, which was nearly complete in mature B and T lymphocytes ( Supplementary Fig. 10a ), prevented STAT3 activation in regressing tumours, but did not affect extracellular signal-regulated kinase (ERK) and AKT activation (Supplementary Fig. 10b ). Immunohistochemical analysis confirmed STAT3 activation in CaP cells, which was inhibited by A490 (Supplementary Fig. 10c ), an inhibitor of STAT3 phosphorylation 18 that delayed appearance of castration-resistant CaP ( Supplementary Fig.  10d ) but did not inhibit IKK activation ( Supplementary Fig. 11a ). Conversely, ML120B did not inhibit STAT3 activation (Supplementary Fig. 11b ).
Ablation of bone-marrow-derived cell IKK-b did not prevent leukocyte recruitment into regressing tumours ( Supplementary Fig. 12 ) but did inhibit cytokine induction ( Supplementary Fig. 13 ). To investigate the role of lymphocytes further, we used chimaeric mice generated by transplantation of bone marrow from lymphocyte-deficient Rag1 -/-mice. Although primary tumour growth was identical in mice receiving wild-type or Rag1 -/-bone marrow ( Supplementary Fig. 14a ), castration-resistant CaP growth was significantly delayed in mice receiving Rag1
-/-bone marrow (Fig. 2a ), but not in mice reconstituted with bone marrow from Tcrb Supplementary Fig. 14b ), which lack only mature T lymphocytes. Castration-resistant CaP growth was delayed in mice reconstituted with bone marrow from J H -/-mice ( Supplementary Fig. 14c ), which lack mature B cells, or upon B-cell depletion with CD20 antibody 19 ( Supplementary Fig. 14d ).
Reconstitution of Rag1
-/-FVB mice with splenic B cells, but not T cells of FVB mice, restored rapid castration-resistant CaP re-growth (Fig. 2a) . Primary tumours, isolated from Rag1 -/-chimaeric mice 1 week after castration, did not show STAT3 activation (Fig. 2b ), but reconstitution with B cells, rather than T cells, restored castrationinduced STAT3 phosphorylation (Fig. 2c) .
CaP allografts from castrated, but not sham-operated, mice exhibited IKK-a nuclear translocation (Fig. 3a, b) . Silencing of IKK-a in myc-CaP cells using short interfering RNA (siRNA) ( Supplementary Fig. 15a ) had little effect on primary tumour growth, but delayed emergence of castration-resistant CaP (Fig. 3c) . Nuclear translocation of IKK-a was dependent on IKK-b in bone-marrow-derived cells and on B cells, but not on T cells (Fig. 3d ). IKK-a nuclear translocation parallels progression of human and murine CaP and coincides with primary tumour infiltration with cells expressing IKK-a-activating cytokines, RANK ligand and lymphotoxin-a 11 . Castration induced lymphotoxin-a and lymphotoxin-b in regressing myc-CaP allografts, but did not alter RANK ligand expression ( Supplementary Fig. 7 ). Lymphotoxin expression in regressing tumours was absent in Rag1 -/-mice ( Supplementary  Fig. 16a ), and flow cytometry localized it to tumour-infiltrating B cells (TIBCs; Supplementary Fig. 16b ). We characterized TIBCs by sevencolour flow cytometry with several markers and a lymphotoxin-b receptor-immunoglobulin fusion protein (LTbR-Ig) to detect lymphotoxin. The typical TIBC was a conventional, mature B2 cell that expressed lymphotoxin on its surface and was negative for B1 markers ( Supplementary Fig. 17 ). IKK-b deletion abolished lymphotoxin expression by B cells (Fig. 4a) , supporting the previously suggested 20 role of NF-kB in lymphotoxin-a/b induction. To examine whether lymphotoxin production by tumour-infiltrating lymphocytes stimulates castration-resistant CaP growth, we transplanted bone marrow from B-Ltb -/-or T-Ltb -/-mice, which lack lymphotoxin-b in either B or T cells 21 , into lethally irradiated mice. Lymphotoxin-b ablation in B Six-week-old FVB males (n 5 10) were inoculated with myc-CaP cells. When tumours reached 1,000 mm 3 , mice were left untreated, castrated or shamoperated. Tumours were collected when indicated for analysis. a, Paraffinembedded tumour sections were stained by TdT-mediated dUTP nick end labelling (TUNEL) to determine apoptotic cell frequency (results are averages, n 5 3). b, Total RNA was isolated from tumour samples and expression of indicated cell-marker mRNAs was quantified and normalized to that of cyclophilin A (norm, normal; C1, 2, 3, mice analysed 1, 2 or 3 weeks after castration; sham, sham-operated). Results are averages 6 s.d. (n 5 10). c, Frozen human prostate sections (normal tissue (n 5 3), prostatic hyperplasia (n 5 3) and malignant CaP with Gleason scores 6-8 (n 5 10)) were stained with CD4, CD8 and CD20 antibodies and 49,6-diamidino-2-phenylindole (DAPI) and analysed by immunofluorescent microscopy. The histogram denotes average frequencies of indicated cell types (n 5 3 per sample). P values were determined and are depicted as insignificant, significant (*), very significant (**) or highly significant (***). Original magnifications, 320 (a, c).
p p p cells, but not in T cells, delayed growth of castration-resistant CaP (Fig. 4b) and abolished lymphotoxin-b expression within tumours but did not prevent B-cell or macrophage infiltration (Supplementary Fig. 18 ). Treatment of mice with the LTbR-Ig decoy 22 was as effective as B-cell-specific lymphotoxin-b ablation in delaying growth of castration-resistant CaP (Fig. 4c) and prevented IKK-a and STAT3 activation (Supplementary Fig. 19 ). Silencing of LTbR in Myc-CaP cells (Supplementary Fig. 15b ) also delayed growth of castration-resistant CaP (Fig. 4d) . Exogenous lymphotoxin maintained myc-CaP growth in the presence of flutamide, a clinically used androgen-receptor antagonist 3 , in a manner dependent on IKK-a (Fig. 4e) , whose nuclear translocation was lymphotoxin inducible (Fig. 4f) .
W WT + WT + WT WT T T + WT + T + WT T + T + T + + WT WT WT T + T T WT T T + + T + WT T T T T T + T + T WT + T T + T T + T + T + + + WT + WT WT T + T T T + + + T + WT WT + T T T + T T T T + + WT T T T T + + WT + T T + T + + + + + WT + + T T T T T T + T T WT T T T Ikk kk kk k Ikk Ik Ik k kk
Castration-resistant CaP is a major complication that limits the success of androgen ablation therapy and is responsible for most mortality from prostate cancer 2 . Castration-resistant CaP was studied mainly at the level of androgen-receptor function, the central player in this process 4 . Our results suggest that an inflammatory response triggered by death of androgen-deprived primary cancer is another important contributor to emergence of castration-resistant CaP. In addition to dying CaP cells, critical participants in this response are tumour-infiltrating B cells, which produce lymphotoxin-a:b heterotrimers that stimulate LTbR on CaP cells to induce IKK-a nuclear translocation and STAT3 activation, thereby enhancing androgenindependent growth (Supplementary Fig. 20) . Interference with any component of this response results in a significant and reproducible 3-to 4-week delay in appearance of castration-resistant CaP. Although these inhibitory effects are not absolute, extrapolation from 'mouse time' to 'human time' suggests that interventions that prevent lymphotoxin production or signalling may delay appearance of castrationresistant CaP in patients undergoing androgen ablation therapy by 2.3 to 3.1 years. Importantly, our results suggest that, at least for CaP, the inflammatory response elicited by the dying primary tumour contributes to the failure rather than the previously proposed success of anticancer therapy 23 . Although we have not determined how death of androgen-deprived CaP triggers the inflammatory response described above, necrotic cell death releases mediators, such as HMGB1 (ref. 24) and IL-1a (ref. 25) , that activate IKK-b and NF-kB and stimulate production of chemokines, one of which, CXCL13, recruits B cells into the regressing tumour. Notably, TIBCs were detected not only in androgen-deprived mouse CaP, but also in human CaP. Although B cells were reported to promote progression of skin carcinomas 9 and exert immunosuppressive effects through activation of inhibitory Fc receptors on myeloid cells 26 , the critical tumour-promoting B-cell function in our experimental model is production of lymphotoxin, Tumour-bearing mice were castrated or sham operated as above. a, Tumours were analysed 1 week later for nuclear IKK-a by immunohistochemistry. b, Tumours removed at indicated times were divided into cytosolic (C) and nuclear (N) fractions, and IKK-a and histone H3 distributions determined. an IKK-a-activating cytokine 27 , which promotes survival of androgendeprived CaP. Another important function of TIBCs is activation of STAT3, an anti-apoptotic and pro-tumorigenic transcription factor 28 . Although the critical STAT3-activating cytokine in this system remains to be identified, castration induces expression of STAT3-activating IL-6 and IL-12 family members. Furthermore, CaP cells use autocrine IL-6 to stimulate their progression 29 and activated STAT3 promotes ligand-independent androgen-receptor activation 29 . Lymphotoxin is also involved in the aetiology of human CaP. An epidemiological study revealed that reduced CaP risk due to consumption of non-steroidal anti-inflammatory drugs, such as aspirin, is limited to men who express a common polymorphic LTa allele that specifies high lymphotoxin production 30 . Further work should examine the effect of LTa polymorphism on the response to androgen ablation. Our results predict that individuals who produce high levels of lymphotoxin are more likely to develop castration-resistant CaP and should therefore be the main beneficiaries of anti-lymphotoxin therapy.
METHODS SUMMARY
Mice were handled according to institutional and National Institutes of Health guidelines. Tumours were grown in FVB mice. Where indicated, lethally irradiated FVB mice were reconstituted with bone marrow from different strains that were backcrossed into the FVB background for at least two generations. Ltb knockout strains were, however, in the BL6 background, which does not elicit a graft versus host response in FVB mice. Conditions for antibody used were posted to http://biorating.com. Human material was obtained from the Cooperative Human Tissue Network, along with pathology reports. Histology, gene expression and cell signalling were analysed as described 11, 25 .
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
